Brian Brimhall
Psychiatric/Mental Health · Idaho Falls, IDNPI 1245796101
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,832 of the $5,613 with a category attached, or 86.1%. 19 manufacturers reported payments, led by AbbVie at 25.7% of the total. 2025 is the largest year on record at $1,770, 4.1 times the $433 reported in 2021. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$830
- Vanda Pharmaceuticals Inc.$425
- Otsuka America Pharmaceutical, Inc.$304
- Alkermes, Inc.$267
- plus $1K from 13 others
What the payments were for
- Travel & lodging$71413%
- Food & beverage$4,83286%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 99 | $1,442 |
| Johnson & Johnson | 18 | $1,143 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $830 |
| Vanda Pharmaceuticals Inc. | 19 | $425 |
| Otsuka America Pharmaceutical, Inc. | 15 | $304 |
| Alkermes, Inc. | 13 | $267 |
| Lundbeck LLC | 14 | $224 |
| Neurocrine Biosciences, Inc. | 9 | $180 |
| Axsome Therapeutics, Inc. | 8 | $160 |
| Teva Pharmaceuticals USA, Inc. | 8 | $157 |
| Supernus Pharmaceuticals, Inc. | 8 | $144 |
| Indivior Inc. | 6 | $115 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Corium, LLC | 2 | $30 |
| Boehringer Ingelheim | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$814
How this compares
$5,613 in reported general payments places this provider in the 90th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 71 | $99,203 |
| CaplytaLumateperone Tosylate | 58 | $89,707 |
| Invega SustennaPaliperidone Palmitate | 15 | $50,878 |
| Risperdal ConstaRisperidone Microspheres | 11 | $26,663 |
| Abilify MaintenaAripiprazole | 12 | $23,799 |
| SpravatoEsketamine Hcl | 12 | $23,307 |
| RexultiBrexpiprazole | 12 | $16,925 |
| Paliperidone ErPaliperidone | 35 | $16,923 |
| Lurasidone Hcl | 70 | $11,320 |
| TrintellixVortioxetine Hydrobromide | 20 | $9,602 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 29 | $6,340 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $6,159 |
| BelsomraSuvorexant | 15 | $5,795 |
| Lisdexamfetamine Dimesylate | 35 | $5,517 |
| Atomoxetine Hcl | 26 | $3,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Spravato | $1,143 | $100,84938 claims |
| AbbVieVraylar | $1,442 | $99,20371 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $830 | $89,70758 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $304 | $40,72424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $56 | $15,76140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Idaho Falls
- Jason MartinIdaho Falls$78K
- Todd BatesIdaho Falls$4K
- Robert GreenigIdaho Falls$3K
- Amber van Sickle-BirchIdaho Falls$2K
- Misti NewsonBoise$56K
- Jared PetrickCoeur D Alene$32K
- Carey CrillBoise$19K
- Deborah RushMeridian$13K
- Ashley CroftCaldwell$13K
- Scott WatkinsNampa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.